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KEY POINTS 
 FNH and HCA own different tissue expression of hepatocyte transporters
involved in Gd-EOB-DTPA-enhanced MRI pharmacodynamics 
 HCA with lower and higher risk of malignant transformation and HCA-HCC
have specific hepatocyte transporters expression profiles 
 Translational radiological criteria based on Gd-EOB-DTPA uptake can help to
stratify HCA according to their risk of malignant transformation 
Abstract 
Background & Aims: Hepatobiliary phase (HBP) Gd-EOB-DTPA-enhanced 
magnetic resonance imaging (MRI) has increased the accuracy in differentiating 
focal nodular hyperplasia (FNH) and hepatocellular adenoma (HCA). However, the 
ability of this technique to distinguish HCA subtypes remains controversial. The aim 
of this study was to investigate the expression of hepatocyte transporters 
(OATPB1/B3, MRP2, MRP3) in HCA subtypes, hence to understand their MRI signal 
intensity on HBP Gd-EOB-DTPA-enhanced MRI. 
Methods: By means of immunohistochemistry (IHC) we scored the expression of 
OATPB1/B3, MRP2 and MRP3, in resected specimens of FNH (n=40), subtyped 
HCA (n=58) and in HCA with focal malignant transformation (HCA-HCC, n=4). 
Results were validated on a supplementary set of FNH (n=6), subtyped HCA (n=17) 
and HCA-HCC (n=1) with Gd-EOB-DTPA MR images. 
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Results: All FNH showed a preserved expression of hepatocytes transporters. Beta-
catenin activated HCA (at highest risk of malignant transformation) and HCA-HCC 
were characterized by preserved/increased OATPB1/B3 expression (predictor of 
hyperintensity on HBP), as opposed to other HCA subtypes (p<0.01) that mostly 
showed OATPB1/B3 absence (predictor of hypointensity on HBP). HCA-HCC 
showed an additional MRP3 overexpressed profile (p<0.01). On HBP Gd-EOB-
DTPA-enhanced MRI, FNH and HCA signal intensity reflected the profile predicted 
by their specific OATPB1/B3 tissue expression. The hyperintense vs. hypointense 
HBP signal criterion was able to distinguish all higher risk HCA and HCA-HCC 
0% accuracy). 
Conclusions: OATPB1/B3 and MRP3 IHC and signal intensity on HBP Gd-EOB-
DTPA-enhanced MRI can help to stratify HCA according to their risk of malignant 
transformation. 
KEYWORDS: Hepatocellular adenoma, radio-pathological correlation, hepatocyte 
transporters, hepatospecific magnetic resonance imaging. 
Introduction 
Focal nodular hyperplasia (FNH) and hepatocellular adenoma (HCA), the two 
prototypical benign hepatocellular nodules, share common clinical context (child 
bearing women, history of oral contraception) and liver background (normal or non-
cirrhotic).1-4 However, unlike FNH, HCA is a true neoplastic process, entailing risk of 
bleeding and malignant transformation.5,6 In the last two decades, the oncogenic 
mechanisms activated in HCA have been characterized with molecular biology 
techniques, generating gene signatures translated in a molecular classification.7-10 
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According to the latter, HCA is divided into 4 subgroups, showing specific 
morphology, immunohistochemical phenotype, molecular background, clinical 
settings and natural history: HNF1a inactivated HCA (H-HCA), inflammatory HCA 
(IHCA) b-catenin activated HCA (b-HCA), and argininosuccinate synthase 1-
positive/sonic hedgehog HCA (ASS1+HCA).8,11-13 H-HCA without classical steatosis 
(atypical H-HCA), mixed b-catenin activated and inflammatory HCA (b-IHCA) and 
HCA with focal transformation into hepatocellular carcinoma (HCA-HCC) are also 
observed. B-HCA and b-IHCA own the highest risk of malignant transformation due 
to their b-catenin (CTNBB1) exon 3 gene mutation, with a reported odds ratio of 
9.3.12,14
Therefore, the differential diagnosis between FNH and HCA, and a correct 
classification of HCA subtype, are important for a tailored management strategy.15,16 
In the current clinical practice, this task is mainly based on radiology, with magnetic 
resonance imaging (MRI) being the most valuable tool, and liver biopsy only 
performed in case of doubt.17-20 However, MRI is less effective in the characterization 
of the HCA subtype (85% of correct diagnosis in the most performant series), 
prompting liver biopsy and pathological analysis, or proceed towards resection with 
the sole criterion of >5cm lesion size in a significant fraction of cases.17,21 
The introduction of hepatobiliary phase (HBP) Gd-EOB-DTPA-enhanced MRI has 
improved the diagnostic performance in the differential diagnosis of HCA vs. FNH, 
with a reported 91-100% sensitivity and 87-100% specificity.22-25 Gd-EOB-DTPA is a 
hepatospecific contrast agent transported through hepatocytes by hepatocyte 
transporters proteins (HT), namely organic anion-transporting polypeptides B1/B3 
(OATPB1/B3) and multidrug resistance associated proteins 2 and 3 (MRP2, 
MRP3).26 OATPB1/B3 is expressed at hepatocytes basolateral pole and allows the 
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contrast agent influx/backflux from and to the sinusoidal space; MRP3 is also 
expressed at the basolateral pole, allowing a complementary sinusoidal backflux; 
MRP2 is expressed at hepatocytes canalicular pole and is responsible of biliary 
efflux. 
27,28 At imaging, FNH accumulates Gd-EOB-DTPA during the HBP (data acquisition 
at 20 minutes after venous injection), showing iso or hyperintensity as compared to 
the surrounding liver.27,29,30 By contrast, according to the literature, the HCA Gd-
EOB-DTPA uptake profile is controversial. Only a few studies aimed to elucidate this 
phenomenon, showing mostly a hypointense profile.27,29-32 In a recent radio-
pathological report, it has been suggested that, in HCA, the degree of OATPB1/B3 
and MRP3 expression correlated respectively with Gd-EOB-DTPA “retention” and 
“washout” seen on HBP MR images.33 However, a precise pathological 
aracterization of HT expression patterns in HCA subtype according to the most 
recent classification, particularly in HCA with less common phenotypes (atypical H-
HCA, ASS1+HCA), and with higher risk of malignant transformation (b-IHCA, b-HCA) 
and HCA-HCC is unclear. Aim of this study was to detail the expression of HT in 
FNH and HCA subtypes, and to investigate their signal intensity on HBP Gd-EOB-
DTPA-enhanced MRI. 
Materials and Methods 
Cases under study 
Study set: to characterize the HT expression of FNH and HCA, we collected 102 
hepatocellular nodules (40 FNH, 58 HCA, 4 HCA-HCC), resected from 95 non-
cirrhotic patients between 1995 and 2016. Material and clinical information were 
retrieved from the archives of Policlinico Maggiore, San Paolo, Istituto Europeo di 
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Oncologia and Istituto Nazionale dei Tumori hospitals (Milan, Italy) and Pellegrin 
Hospital (Bordeaux, France). Two liver pathologists reviewed all the original 
materials at the Lausanne University Hospital and classified nodules as FNH or 
HCA, then subtyped HCA with immunohistochemistry according to the most recent 
classification.8,13  
Validation set: to verify the Gd-EOB-DTPA intensity predicted by the study set 
results we reviewed 6 FNH, 17 HCA and 1 HCA-HCC from Lausanne University 
Hospital, comparing their preoperative hepatospecific MRI with postoperative 
pathological classification. 
The diagnosis of HCA-HCC was retained only in cases with presence of evident 
HCC in otherwise undoubtful HCA. Evident HCC showed a combination of severe 
cytological atypia, thick (>3 hepatocytes) cell plates and prominent pseudoacinar 
architecture with bile plugs, in association with loss of the reticulin framework. The 
study protocol was in accordance with the recommendations of national and 
cantonal ethical committees and with the declaration of Helsinki. For Italian centers, 
informed consent and ethical committees approval was unneeded (G.U. 72 26 March 
2012). For Pellegrin Hospital, patients informed consent and ethics approval by the 
local committee of "Direction de la Recherche Clinique et de l'Innovation" (Bordeaux 
University Hospital, Bordeaux, France; Liver Biobank of CHU Bordeaux, n° BRIF: 
BB-0033-00036) were obtained. For the Lausanne University Hospital, the 
Institutional Review Board and Human Research Ethics Committee of the University 
Hospital of Lausanne, Switzerland approved this retrospective study and patients' 
active consent was waived (protocol 483/13). 
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Immunohistochemistry 
For all cases, centers involved in the study provided three consecutive recuts from 
the original paraffin blocks that were stained with antibodies against OATPB1/B3, 
MRP2 and MRP3 (detailed in Table S1), following standard procedures. In all 
specimens, extralesional liver tissue was available for the pathological analysis and 
served as internal positive control. Two observers (C.S., A.S.) independently 
assessed the HT staining on each nodule. Consensus was obtained after discussion 
at multihead microscope in discordant cases. The HT staining pattern was 
descriptively reported and a semiquantitative evaluation was performed according to 
the following criteria: 0= HT not expressed, as opposed to adjacent non tumoral liver; 
1= HT expressed similarly to adjacent liver; 2= HT increased expression as 
compared to the adjacent liver. Fig. S1 illustrates visual references for this 
semiquantitative analysis. 
Gd-EOB-DTPA-enhanced MR image analysis 
Unaware of the results of the pathological study set cases, an expert radiologist, with 
15 years experience in liver MRI (S.S.) reviewed Gd-EOB-DTPA-enhanced MR 
images of the validation set cases. Each nodule was visually classified on HBP as 
being either hypointense, isointense or hyperintense in comparison with the 
surrounding liver parenchyma. 
Statistical Analysis 
Variables were reported as numbers and percentages and summarized as mean (± 
SD) or median with interquartile range (IQR). We compared groups using the Mann-
Whitney, χ2 or Fisher exact tests, as appropriate. Tests were two-sided and we used 
This article is protected by copyright. All rights reserved. 
a significance level of 0.05. Analyses were performed with R software and SPSS 
23.0 (®2013 SPSS Inc., Chicago, IL, USA). 
Results 
Clinico-pathological data 
The 95 study set patients were mostly female (88%), with a median age of 37 years 
(IQR 11), all without history of previous primary liver tumor. Clinically, a fraction of 
patients showed metabolic (19%) or circulation (17%) disorders. History of oral 
ntraception was recorded in 35/84 (42%) female patients. For diagnostic purpose, 
in most cases, two or more imaging techniques were used, with CT and non-
hepatospecific MRI performed in 79/95 (83%) cases. At pathological analysis 
(resected specimens), fatty or vascular liver disease was observed in 34/95 (36%) 
cases, while no patient showed advanced fibrosis, cirrhosis or chronic liver disease 
of other origins. Median pathological lesional size was 3 cm (IQR 8.3). As compared 
to FNH, HCA grouped more patients with OC history (51% vs. 17%, p=0.001), 
multiple (44% vs. 15%, p=0.003) and larger lesions (5.8 vs. 4 cm, p=0.009). Clinico-
pathological parameters according to FNH or HCA diagnosis in the study set are 
indicated in Table 1. Clinico-pathological parameters of 24 patients included in the 
validation set did not significantly differed from the study set ones (data not shown). 
HCA subtyping 
Study set (n=62): 24 H-HCA (38.7%), 4 atypical H-HCA (6.5%), 15 IHCA (24.2%), 4 
ASS1+HCA (6.4%), 5 b-HCA (8.1%), 6 b-IHCA (9.7%), and 4 HCA-HCC (6.4%). 
HCA-HCC originated from b-HCA in 3 cases and b-IHCA in one case. 
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Validation set (n=18): 3 H-HCA, 8 IHCA, 4 ASS1+HCA, 2 b-HCA, and 1 HCA-HCC 
originating from a b-HCA. 
Beta-catenin activated HCA displayed strong glutamine synthetase staining 
congruent with CTNNB1 exon 3 mutations. 
Study set: HT expression in FNH vs. HCA 
All FNH expressed the three HT, with a periseptal staining pattern. HT staining was 
similar to adjacent extralesional liver tissue (score=1), but more diffuse in 
hepatocytes at the interface with fibrosis. The subcellular pattern was preserved 
(OATPB1/B3 and MRP3 basolateral, MRP2 apical), but an extension to other parts 
of the cell membrane could be observed for OATPB1/B3 and MRP3 in the periseptal 
area. Ductular reaction was strongly immunoreactive for MRP2 and MRP3. Fig. 1 
illustrates HT expression in FNH. In HCA, the three HT expression was variable, 
either lost, present or increased (score 0, 1 or 2), significantly differing from FNH 
(p<0.001). When HT were present, the subcellular pattern of staining could be 
modified (not polarized, without specific topographical distribution on cell 
membrane). Notably, the majority (71%) of cases were OATPB1/B3 negative. HT 
expression in FNH and HCA is summarized in Table 2. In the adjacent liver, HT 
staining was preserved in all cases (internal positive control), not modified even in 
presence of vascular or fatty liver disease. 
Study set: HT expression in HCA subtypes 
Typical and atypical H-HCA (n=28) showed similar OATPB1/B3 loss (100% 
score=0).  MRP2 was also mostly lost in both groups (87% and 75% score=0) 
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whereas a remarkably different MRP3 expression was observed (score=0 in 92% of 
typical vs. 25% of atypical H-HCA, p=0.025). 
IHCA (n=15) showed OATPB1/B3 loss in a majority of the cases (86.7% score=0) 
while MRP2 and MRP3 expression was preserved or increased (100% score=1 or 2, 
for both). ASS1+HCA (n=4), showed OATPB1/B3 and MRP3 loss in a majority of the 
cases (75% score=0), and preserved MRP2 expression (100% score=1). HT 
expression in these subgroups of HCA at lower risk of malignant transformation is 
illustrated in Fig. 2. 
HCA with higher risk of malignant transformation (b-HCA, b-IHCA) presented a 
preserved or increased OATPB1/B3 expression: b-HCA (n=5, 100% score=2), b-
IHCA (n=6, 100% score=1 or 2). By contrast with FNH, the preserved OATPB1/B3 
(score 1) expression in 4 b-IHCA, as well as in 2 IHCA, was more diffuse, with no 
enhancement in the hepatocytes located at the interface with fibrosis (pseudo-portal 
tracts). 
MRP2 was always present (100% score =1 or 2) and MRP3 was lost in b-HCA 
(100% score=0) and preserved in b-IHCA (100% score=1). 
Finally, HCA-HCC (n=4) showed increased OATPB1/B3 expression (100% score=2), 
preserved or increased MRP2 expression (100% score 1 or 2) and mostly increased 
MRP3 expression (66% score 2). HT profile of higher risk HCA and HCA-HCC is 
illustrated in Fig. 3 and HT expression for all HCA subtypes is detailed in Table 3. 
Thus, OATPB1/B3 score=1 or 2 (predictive of hyperintense HBP) was suggestive of 
HCA with higher risk of malignant transformation (p<0.001) and the association of 
OATPB1/B3 score=2 (predictive of hyperintense signal on HBP MR images) with 
additional MRP3 score=2 (predictive of Gd-EOB-DTPA retention at HBP) was 
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suggestive of HCA-HCC (p<0.001). A scheme of the expected radiological findings in 
HCA subtypes derived from our results is illustrated in Fig. 4. 
Validation Set 
All FNH were iso/hyperintense on HBP Gd-EOB-DTPA-enhanced MR images 
compared to the adjacent liver due to intracellular contrast agent uptake. Intensity 
was mostly heterogeneous, reflecting the presence of intralesional fibrous septa. All 
H-HCA, IHCA and ASS1+HCA were hypointense on HBP due to the absence of 
intracellular Gd-EOB-DTPA uptake. The two b-HCA and the one HCA-HCC were 
hyperintense on HBP Gd-EOB-DTPA-enhanced MR images as compared to 
adjacent liver. Accordingly, HBP Gd-EOB-DTPA-enhanced MRI was able to identify 
HCA at higher risk for malignancy with a sensitivity, specificity and accuracy of 
100%. Examples of the HBP Gd-EOB-DTPA MRI features of FNH, HCA and HCA-
HCC from the validation set are illustrated in Fig. 5. 
Discussion 
In this study, we focused on the translational use of HT expression to clarify the 
features of FNH and HCA observed on the HBP of Gd-EOB-DTPA-enhanced MRI. 
Our working hypothesis was that the reported controversial MRI findings in HCA 
might rely on a different HT expression according to HCA subtype. To our 
knowledge, this is the first study aimed to outline HT expression in a large series of 
resected FNH and HCA, classified with updated criteria, including rare subtypes and 
with an independent external radio-pathological validation set. 
We observed that HT expression in FNH is characterized by a periseptal pattern, 
with little variation in different cases, matching the iso/hyperintense contrast uptake 
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on the HBP of Gd-EOB-DTPA-enhanced MRI that is consistently reported in the 
literature.24,25,27,30,32,34 By contrast, in HCA, HT expression is heterogeneous, 
resulting in a variable intracellular uptake of the hepatospecific contrast agent.27 Our 
results refine those reported in a previous study, based on outdated pathological 
classifications, showing consistently low OATPB1/B3 mRNA levels and IHC 
expression in 9 HCA.31 Independently from the subtype, we noted that 
approximatively 70% of HCA did not display OATPB1/B3 expression. Thus, our 
results suggest that the “no HBP uptake” criterion proposed in several radiological 
papers is indeed generally helpful to separate FNH from the majority of HCA.32,35,36 
These observations are in accordance with those reported in a systematic review, 
showing that FNH have iso- or high signal, while most HCA have low signal on HBP 
as compared to the background liver.23 These authors also suggested that the 
hypersignal in FNH is due to higher expression of OATP transporters as compared 
to HCA, which is confirmed by the present study.23  
In accordance with a previous report by Fukusato et al., when HT profile was 
investigated in different HCA subtypes, we found that in HCA at higher risk of 
malignant transformation (b-IHCA, b-HCA) and in HCA-HCC, OATPB1/B3 
expression is present or increased, as compared to the adjacent liver.37 This result 
can be of translational interest, as OATPB1/B3 staining could be helpful in stratifying 
HCA according to their risk of malignancy. As such, OATPB1/B3 staining on a liver 
nodule could potentially be a supplementary tool in tailoring the patient management. 
In the study set, H-HCA, typical and atypical, showed a homogenous loss of 
OATPB1/B3. This subcategory of atypical H-HCA, characterized at the histological 
level by loss of steatosis and focal pseudoglandular architecture, is not well 
understood. By contrast to typical H-HCA, the increased MRP3 expression that we 
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found in this entity underlines a specificity deserving further investigation. Similarly, 
all but 2 IHCA showed loss of OATPB1/B3 expression. The persistence of 
OATPB1/B3, paired with consistent presence of MRP2 and MRP3 expression in a 
few IHCA and more frequently b-IHCA, suggest that a few of them can have an 
imaging overlap with FNH, somehow recalling the outdated nomenclature of IHCA as 
“telangiectatic FNH”.38 The final diagnosis of IHCA and b-IHCA rely on a multimodal 
approach, including conventional morphology and immunohistochemistry. In 
addition, in IHCA and b-IHCA with preserved (score 1) OATPB1/B3 expression, the 
pattern of staining differed from the one of FNH, which was enhanced in periseptal 
areas. 
Little is known on the clinical behavior of ASS1+HCA, except for their predisposition 
to bleeding.12,13 The majority of them in this study showed loss of OATPB1/B3, 
grouping them with H-HCA and IHCA. 
We then validated these observations in an independent cohort with radio-
pathological data. In these patients, the Gd-EOB-DTPA uptake profile was congruent 
with the one predicted by the study set results: FNH were all iso/hyperintense, HCA 
at higher risk of malignant transformation showed hyperintense signal and other 
HCA were characterized by a hypointense signal. These findings, even if based on a 
relatively limited number of observations, suggest that signal intensity may be a 
surrogate marker of OATPB1/B3 presence or loss. In agreement with our results, 
Ba-Ssalamah et al. reported Gd-EOB-DTPA “retention” in 83% of b-HCA on the HBP 
of Gd-EOB-DTPA-enhanced MRI, while they inconsistently observed this 
hyperintensity in other HCA subtypes.33 However, this series did not include all 
subtypes. Recently, Reizine et al. reported similar results with a signal intensity 
quantitative analysis on Gd-BOPTA imaging.39 Since high-risk HCA showed a 
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hyperintense signal on the HBP of Gd-EOB-DTPA-enhanced MR images in our 
study, the radiological differentiation from hyperintense FNH should also rely on 
other MRI features, such as the heterogeneous “periseptal” uptake of FNH on HBP, 
the presence of a central scar, or other MR phases features. Indeed, unlike FNH, b-
HCA typically demonstrate a subtle heterogenous hypersignal on T2-weighted MR 
images.33 In some cases, the final answer will require the pathological analysis of a 
biopsy.20 
The molecular mechanism underpinning OATPB1/B3 expression (and finally HBP 
hyperintense signal) in HCA at higher risk of malignancy has not yet been 
investigated. A review of the MR features seen on HBP in benign hepatocellular 
nodules suggested a mechanistic link between the activation of the Wnt/b-catenin 
pathway and OATPB1/B3 expression based on experimental studies on animal 
models.40-42 This potential link seems really appealing, as the activation of this 
molecular pathway could explain the hyperintense signal observed in FNH (non-
mutant Wnt/ b-catenin activation), b-IHCA and b-HCA (mutant Wnt/ b-catenin 
activation).40 
The functional role of MRP2 and MRP3 in FNH and HCA is more controversial. Their 
activity is expected to rely on OATPB1/B3 function (no efflux and backflux without 
uptake) and the reported absence of physiological connection with the biliary tree in 
FNH and HCA suggests that no biliary efflux through MRP2 is possible.31,33 MRP3 
can be involved in the hepatospecific contrast agent release into the sinusoids of 
hyperintense hepatocellular lesions. In our series, all HCA-HCC showed OATPB1/B3 
expression and, in two cases, increased MRP3 expression was also found, 
suggesting a shorter retention of hepatospecific contrast agent in these lesions. As 
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HCA-HCC are early malignant lesions, our results seem in accordance with those of 
Kitao et al., who suggested that OATPB1/B3 expression decreases with tumor 
dedifferentiation, being more intense in early stage HCC.43,44 To date, no evidence is 
available to clarify the reason of MRP3 expression in HCA-HCC, but the MRP3 
overexpression reported in cholestatic liver disease can draw an intriguing link 
between MRP3 expression and cholestatic features (such as bile thrombi formation) 
observed in HCA-HCC.26,45 Interestingly, in mouse models, it has been shown that 
the hepatocyte-specific expression of an oncogenic variant of b-catenin (originated 
through exon 3 deletion of CTNBB1, comparable to mutant exon 3 CTNBB1 of 
human b-HCA), results in cholestatic liver disease and eventually therefore to 
increased MRP3 expression.46,47 
In conclusion, our results suggest that the tissue expression of HT in FNH and HCA 
subtypes correlates with signal intensity observed on HBP of Gd-EOB-DTPA-
enhanced MRI. In HCA, the signal intensity at HBP together with the 
immunohistochemical staining for OATPB1/B3 and MRP3, that remains to be 
validated on biopsies, could be useful in identifying HCA at risk of malignant 
transformation and help in stratifying patient for a tailored management. Our results, 
in particular the radio-pathological comparison, should be further validated, 
especially in the light of the low number of cases for some HCA subtypes. This 
validation study should prospectively compare the hepatospecific MR features and 
the expression of hepatocyte transporters in biopsies of a large series of HCA, 
specifically focusing on higher risk lesions, in close comparison with their clinical 
follow-up. 
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Figure legends 
Fig. 1. Study set: hepatocyte transporters expression in FNH. 
(A) At morphological analysis, FNH displayed intralesional fibrous septa, prominent 
ductular reaction and inflammation (H&E stain, 10x). (B-D) Hepatocyte transporters 
were systematically expressed in periseptal hepatocytes (B, OATPB1/B3 stain, 10x) 
(C, MRP2 stain, 10x) (D) MRP3 stain, 10x). 
Fig. 2. Study set: hepatocyte transporters expression in HCA with lower risk of 
malignant transformation. 
(A) At morphological analysis, this H-HCA shows typical steatotic features (H&E 
stain, 10x)  and (B-D) is characterized by absence of hepatocyte transporters 
expression (B, OATPB1/B3 stain, 10x) (C, MRP2 stain, 10x) (D) MRP3 stain, 10x). 
Fig. 3. Study set: hepatocyte transporters expression in HCA with higher risk 
of malignant transformation and in HCA-HCC. 
(A) Hematoxylin-eosin example of b-HCA (left panel), and HCA-HCC displaying 
malignant features with rosettes formation and bile thrombi (right panel, arrows) 
(H&E stain, 10x). (B-C) The phenotype of these lesions was characterized by 
increased OATPB1/B3 expression (B, OATPB1/B3 stain, 10x) and presence of 
MRP2 expression (C, MRP2 stain, 10x). (D) In b-IHCA and b-HCA (left panel) no 
MRP3 expression was detectable, as opposed to the increased MRP3 expression 
observed in HCA-HCC (right panel) (MRP3 stain, 10x). 
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Fig. 4. Schematic representation of the expected radiological findings in HCA 
subtypes and HCA-HCC. 
Based on our results, H-HCA, IHCA and ASS1+HCA are expected to show a 
hypointense signal on the HBP of Gd-EOB-DTPA-enhanced MRI, as contrast agent 
cannot enter into the hepatocytes due to absence of OATPB1/B3 expression. 
Conversely, b-HCA, b-IHCA and HCA-HCC are expected to show a hyperintense 
signal. A faster sinusoidal excretion might be observed in HCA-HCC because of their 
increased MRP3 expression. 
Fig. 5. Validation set: examples of HBP Gd-EOB-DTPA MRI in FNH, HCA 
subtypes and HCA-HCC. 
(A) FNH. These two (arrows) synchronous heterogeneously iso-hyperintense tumors 
were diagnosed as FNH at pathological analysis (B) FNH (arrowhead) and lower risk 
HCA (arrow). These two synchronous tumors, respectively heterogeneously 
hyperintense and hypointense, were diagnosed as FNH and IHCA at pathological 
analysis. (C) Higher risk HCA. This hyperintense tumor (arrow) was diagnosed as b-
HCA at pathological analysis. (D) HCA-HCC. This centrally necrotic, hyperintense 
tumor (arrows) was diagnosed as HCA-HCC at pathological analysis. 
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Tables 
Table 1. Clinico-pathological parameters according to the pathological 
diagnosis in the 102 hepatocellular nodules. 
Variable Category FNH HCA p 
Gender 
Female 34 (85%) 57 (92%) 
NS 
Male 6 (15%) 5 (8%) 
Age Median (IQR) 37 (9.8) 37 (11.8) NS 
BMI Median (IQR) 24 (4.2) 23 (5.6) NS 
OC
No 30 (83%) 29 (49%) 
0.001 
Yes 6 (17%) 30 (51%) 
Metabolic disorder 
No 32 (80%) 51 (82%) 
NS 
Yes 8 (20%) 11 (18%) 
Circulation disorder 
No 32 (80%) 53 (85%) 
NS 
Yes 8 (20%) 9 (15%) 
Discovery 
Asymptomatic 24 (60%) 41 (66%) 
NS 
Symptomatic 
16 (40%) 21 (34%) 
N. of radiological investigations Median (IQR) 2.0 (0) 2.0 (1.0) NS 
Number of lesions 
Single 34 (85%) 35 (56%) 
0.003 
Multiple 
synchronous 6 (15%) 27 (44%) 
Size (cm) Median (IQR) 4.0 (4.9) 5.8 (5.5) 0.009 
Extralesional liver morphology 
Normal 28 (70%) 37 (56%) 
NS 
Pathological 12 (30%) 25 (44%) 
Legend: BMI: Body mass index; OC: oral contraception. 
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Table 2. Expression score of hepatocyte transporters in FNH and HCA. 
Variable Score FNH (n=40) HCA (n=62) P 
OATPB1/B3* 1 40 (100%) 8 (13.3%) <0.001 
0 or 2 0 52 (86.7%) 
MRP2 1 40 (100%) 28 (45.2%) <0.001 
0 or 2 0 34 (54.8%) 
MRP3* 1 40 (100%) 18 (29.5%) <0.001 
0 or 2 0 43 (70.5%) 
Legend: *: missing value for 2 HCA (OATPB1/B3) and 1 HCA (MRP3). 
Table 3. Expression score of hepatocyte transporters in HCA subtypes and 
HCA-HCC (n=62). 
Variable Score H-HCA 
(n=24) 
Atypical H-
HCA 
(n=4) 
IHCA 
(n=15) 
ASS1+HCA 
(n=4) 
b-HCA 
(n=5) 
b-IHCA 
(n=6) 
HCA-HCC 
(n=4) 
OATPB1/B3* 
0 24 (100%) 4 (100%) 13 (86.7%) 3 (75%) 0 0 0 
1 0 0 2 (13.3%) 1 (25%) 0 4 (66.7%) 0 
2 0 0 0 0 5 (100%) 1 (33.3%) 3 (100%) 
MRP2 
0 21 (87.5%) 3 (75%) 0 0 0 0 0 
1 3 (12.5%) 1 (25%) 14 (93.3%) 4 (100%) 2 (40%) 3 (50%) 1 (25%) 
2 0 0 1 (6.7%) 0 3 (60%) 3 (50%) 3 (75%) 
MRP3* 
0 22 (92%) 1 (25%) 0 3 (75%) 5 (100%) 0 1 (33.3%) 
1 1 (4%) 0 11 (73.3%) 1 (25%) 0 6 (100%) 0 
2 1 (4%) 3 (75%) 4 (26.7%) 0 0 0 2 (66.7%) 
Legend: *missing value for 1 b-IHCA, 1 HCA-HCC (OATPB1/B3) and 1 HCA-HCC (MRP3). 
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